Clinical development

research & development

Most of the drugs developed by Bioprojet are “First in Class,” that is, they head up new pharmacological drug classes. Examples include racecadotril: an enkephalinase inhibitor, pitolisant: an inverse agonist/antagonist of the presynaptic H3 histamine receptor or BP1.4979: a partial agonist of the D3 dopamine receptor.

Since these products are all new chemical entities, most of which have an original action mechanism, a complete preclinical and clinical pharmaceutical development process is carried out in order to obtain marketing authorisation.

The Clinical Development Department located in Paris manages candidate drugs from the Bioprojet Research Centre to carry out clinical trials in humans from phase I to phase III, leading to the regulatory registration for the selected indications.